Martin S. Hirsch, MD
It has now been 7 years since the first clinical descriptions of the acquired immunodeficiency syndrome (AIDS), 4 years since HIV-1 was established as its cause, and 2 years since zidovudine (azidothymidine, Retrovir) was shown to improve survival from advanced HIV-1 infection (1). Moreover, intensive investigation into the replicative mechanisms of HIV-1 has led to a veritable flood of new agents that inhibit viral replication in vitro and will require further clinical investigation (2, 3). With this flood of information has come a tidal wave of rising public expectations that threatens the ability to conduct controlled clinical trials. An understanding
Learn more about subscription options.
Register Now for a free account.
Hirsch MS. The Rocky Road to Effective Treatment of Human Immunodeficiency Virus (HIV) Infection. Ann Intern Med. 1989;110:1–3. doi: 10.7326/0003-4819-110-1-1
Download citation file:
Published: Ann Intern Med. 1989;110(1):1-3.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only